BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18378390)

  • 1. Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas.
    Kvasha S; Gordiyuk V; Kondratov A; Ugryn D; Zgonnyk YM; Rynditch AV; Vozianov AF
    Cancer Lett; 2008 Jul; 265(2):250-7. PubMed ID: 18378390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
    Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
    Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
    Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
    Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
    Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
    Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation profile of kidney cancer.
    Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
    Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
    Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FHIT expression and hypermethylation in esophageal squamous cell carcinoma.
    Noguchi T; Takeno S; Kimura Y; Uchida Y; Daa T; Yokoyama S; Gabbert HE; Mueller W
    Int J Mol Med; 2003 Apr; 11(4):441-7. PubMed ID: 12632095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
    Shi HR; Wu QH; Suo ZH; Nesland JM
    Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence or reduction of Fhit expression in most clear cell renal carcinomas.
    Hadaczek P; Siprashvili Z; Markiewski M; Domagala W; Druck T; McCue PA; Pekarsky Y; Ohta M; Huebner K; Lubinski J
    Cancer Res; 1998 Jul; 58(14):2946-51. PubMed ID: 9679951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas.
    Tanaka H; Shimada Y; Harada H; Shinoda M; Hatooka S; Imamura M; Ishizaki K
    Cancer Res; 1998 Aug; 58(15):3429-34. PubMed ID: 9699676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas.
    Bugert P; Wilhelm M; Kovacs G
    Genes Chromosomes Cancer; 1997 Sep; 20(1):9-15. PubMed ID: 9290948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methylation status of FHIT gene in plasma and expression of FHIT gene in cancer tissue of cervical cancer patients].
    Ren CC; Miao XH; Yang B; Zhao L; Sun R; Song WQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Oct; 23(5):565-7. PubMed ID: 17029211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [5'CpG island methylation of the suppressor gene p16/CDKN2/MTS1 in renal carcinoma].
    Maestro ML; Del Barco V; Sanz-Casla MT; Moreno J; Zanna I; Redondo E; Fernández C; Resel L
    Arch Esp Urol; 2000 Jun; 53(5):417-23. PubMed ID: 10961005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
    Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of expression of TIMP3 in clear cell renal cell carcinoma.
    Masson D; Rioux-Leclercq N; Fergelot P; Jouan F; Mottier S; Théoleyre S; Bach-Ngohou K; Patard JJ; Denis MG
    Eur J Cancer; 2010 May; 46(8):1430-7. PubMed ID: 20194016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.